BRPI0922888A2 - administração combinada de fármaco - Google Patents
administração combinada de fármacoInfo
- Publication number
- BRPI0922888A2 BRPI0922888A2 BRPI0922888A BRPI0922888A BRPI0922888A2 BR PI0922888 A2 BRPI0922888 A2 BR PI0922888A2 BR PI0922888 A BRPI0922888 A BR PI0922888A BR PI0922888 A BRPI0922888 A BR PI0922888A BR PI0922888 A2 BRPI0922888 A2 BR PI0922888A2
- Authority
- BR
- Brazil
- Prior art keywords
- drug administration
- combined drug
- combined
- administration
- drug
- Prior art date
Links
- 238000001647 drug administration Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08170948 | 2008-12-08 | ||
| PCT/EP2009/065943 WO2010066593A1 (en) | 2008-12-08 | 2009-11-27 | Combined drug administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0922888A2 true BRPI0922888A2 (pt) | 2019-09-24 |
Family
ID=41800658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0922888A BRPI0922888A2 (pt) | 2008-12-08 | 2009-11-27 | administração combinada de fármaco |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20100144853A1 (pt) |
| EP (1) | EP2373344B1 (pt) |
| JP (1) | JP5538423B2 (pt) |
| KR (1) | KR101459181B1 (pt) |
| CN (1) | CN102245211B (pt) |
| AU (1) | AU2009326326B2 (pt) |
| BR (1) | BRPI0922888A2 (pt) |
| CA (1) | CA2744367A1 (pt) |
| IL (1) | IL212603A (pt) |
| MX (1) | MX2011005304A (pt) |
| SG (2) | SG2013089776A (pt) |
| WO (1) | WO2010066593A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103200935A (zh) * | 2010-11-04 | 2013-07-10 | 霍夫曼-拉罗奇有限公司 | 包含2-甲基丙硫代酸s-[2-([[1-(2-乙基丁基)-环己基]-羰基]氨基)苯基]酯和交联羧甲基纤维素钠的组合物 |
| WO2012076443A1 (en) * | 2010-12-08 | 2012-06-14 | F. Hoffmann-La Roche Ag | Liposomal formulation of dalcetrapib |
| RU2014146930A (ru) * | 2012-04-30 | 2016-06-27 | Ф. Хоффманн-Ля Рош Аг | Новый препарат |
| SI2978859T1 (sl) | 2013-03-27 | 2018-10-30 | F. Hoffmann-La Roche Ag | Genetski označevalci za napovedovanje odzivnosti na terapijo |
| MX384679B (es) | 2014-07-30 | 2025-03-14 | Hoffmann La Roche | Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl). |
| CN110390494B (zh) * | 2019-08-13 | 2022-04-26 | 成都理工大学 | 农业区生活垃圾填埋场地下水中“三氮”的溯源方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002096354A2 (en) * | 2001-05-29 | 2002-12-05 | Tap Pharmaceutical Products Inc. | Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin |
| EA200301139A1 (ru) * | 2001-06-21 | 2004-12-30 | Пфайзер Продактс Инк. | Самоэмульгирующиеся препараты ингибиторов белка-переносчика эфиров холестерина |
| WO2003097714A1 (en) * | 2002-05-20 | 2003-11-27 | Ranbaxy Laboratories Limited | Fat binding using inter-polymer complex of glucosamine and polyacrylic acid |
| US20040082675A1 (en) * | 2002-10-28 | 2004-04-29 | Schilling Steven L. | Rigid foams and a process for the production of such foams |
| PT1603553E (pt) * | 2003-03-17 | 2012-02-03 | Japan Tobacco Inc | Composições farmacêuticas de inibidores de cetp |
| WO2004082675A1 (en) * | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate |
| US6987118B2 (en) * | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
| US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| KR20070072888A (ko) * | 2004-10-25 | 2007-07-06 | 니뽄 다바코 산교 가부시키가이샤 | 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법 |
| JP4482692B2 (ja) * | 2005-04-26 | 2010-06-16 | 国立大学法人 熊本大学 | Caco−2細胞を用いたエステル含有化合物の消化管吸収性の予測方法 |
| JP2009514851A (ja) * | 2005-11-08 | 2009-04-09 | ランバクシー ラボラトリーズ リミテッド | (3r,5r)−7−[2−(4−フルオロフェニル)−5−イソプロピル−3−フェニル−4−[(4−ヒドロキシメチルフェニルアミノ)カルボニル]−ピロール−1−イル]−3,5−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法 |
-
2009
- 2009-11-27 BR BRPI0922888A patent/BRPI0922888A2/pt not_active IP Right Cessation
- 2009-11-27 EP EP09764230.0A patent/EP2373344B1/en not_active Not-in-force
- 2009-11-27 CN CN2009801489510A patent/CN102245211B/zh not_active Expired - Fee Related
- 2009-11-27 SG SG2013089776A patent/SG2013089776A/en unknown
- 2009-11-27 CA CA2744367A patent/CA2744367A1/en not_active Abandoned
- 2009-11-27 SG SG2011041407A patent/SG172003A1/en unknown
- 2009-11-27 KR KR1020117012978A patent/KR101459181B1/ko not_active Expired - Fee Related
- 2009-11-27 AU AU2009326326A patent/AU2009326326B2/en not_active Ceased
- 2009-11-27 JP JP2011540012A patent/JP5538423B2/ja not_active Expired - Fee Related
- 2009-11-27 MX MX2011005304A patent/MX2011005304A/es active IP Right Grant
- 2009-11-27 WO PCT/EP2009/065943 patent/WO2010066593A1/en not_active Ceased
- 2009-12-02 US US12/629,086 patent/US20100144853A1/en not_active Abandoned
-
2011
- 2011-05-01 IL IL212603A patent/IL212603A/en not_active IP Right Cessation
-
2015
- 2015-11-05 US US14/933,544 patent/US20160074360A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5538423B2 (ja) | 2014-07-02 |
| CN102245211B (zh) | 2013-05-22 |
| WO2010066593A1 (en) | 2010-06-17 |
| SG172003A1 (en) | 2011-07-28 |
| JP2012511040A (ja) | 2012-05-17 |
| IL212603A0 (en) | 2011-07-31 |
| IL212603A (en) | 2015-09-24 |
| EP2373344B1 (en) | 2016-03-30 |
| SG2013089776A (en) | 2015-07-30 |
| US20100144853A1 (en) | 2010-06-10 |
| MX2011005304A (es) | 2011-06-01 |
| CA2744367A1 (en) | 2010-06-17 |
| KR20110092297A (ko) | 2011-08-17 |
| KR101459181B1 (ko) | 2014-11-07 |
| AU2009326326A1 (en) | 2010-06-17 |
| EP2373344A1 (en) | 2011-10-12 |
| AU2009326326B2 (en) | 2015-05-21 |
| CN102245211A (zh) | 2011-11-16 |
| US20160074360A1 (en) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0920514A2 (pt) | infusão de fármacos | |
| DK2381988T3 (da) | Medikamentadministrationsanordning | |
| BRPI0920521A2 (pt) | combinação farmacêutica | |
| DK2296732T3 (da) | Medikamentafgivelsesindretning | |
| DK2073795T3 (da) | Misbrugssikret lægemiddelformulation | |
| DK2414011T3 (da) | Medikamentafgivelsesindretning | |
| DK2274032T3 (da) | Anordning til medicinindgivelse | |
| DK2274030T4 (da) | Lægemiddelafgivelsesanordning | |
| ATE531410T1 (de) | Arzneimittelabgabevorrichtung | |
| BRPI1010279A2 (pt) | dispositivo de distribuição de fármaco | |
| PL2136865T3 (pl) | Podawanie donosowe | |
| DK2632493T3 (da) | Lægemiddelindgivelsessammensætninger | |
| BRPI0820381A2 (pt) | Formulações farmacêuticas | |
| PL3005986T3 (pl) | Infuzja leków | |
| BRPI1012730A2 (pt) | dispositivo de distribuição de fármaco | |
| SMT201400069B (it) | Formulazione farmaceutica | |
| EP2451274A4 (en) | Pharmaceutical compositions | |
| EP2419097A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| BRPI1010237A2 (pt) | dispositivo de distribuição de fármaco | |
| BRPI0921654A2 (pt) | formulação farmacêutica | |
| PL2379086T3 (pl) | Preparat farmeceutyczny | |
| EP2236149A4 (en) | MEDICAL COMPOSITION | |
| DK2285413T3 (da) | Farmaceutisk sammensætning | |
| BR112012000799A2 (pt) | dispositivo de distribuição de fármaco | |
| DK2437736T3 (da) | Lægemiddelindgivelsessystemer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |